Edition:
India

TRACON Pharmaceuticals Inc (TCON.OQ)

TCON.OQ on NASDAQ Stock Exchange Global Market

2.80USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$2.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22,354
52-wk High
$3.95
52-wk Low
$2.00

Chart for

About

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is... (more)

Overall

Beta: --
Market Cap(Mil.): $61.63
Shares Outstanding(Mil.): 16.66
Dividend: --
Yield (%): --

Financials

BRIEF-Tracon Pharmaceuticals Says Regarding Election Of Ted Wang To Board, Board Approved Increase In Size From Six To Seven Members

* TRACON PHARMACEUTICALS SAYS REGARDING ELECTION OF TED WANG TO BOARD, BOARD APPROVED AN INCREASE IN SIZE FROM SIX TO SEVEN MEMBERS - SEC FILING Source text: (https://bit.ly/2JBtjFa) Further company coverage:

11 Apr 2018

BRIEF-Linden Capital Reports 9.9 Pct Passive Stake In Tracon Pharmaceuticals

* LINDEN CAPITAL L.P. REPORTS 9.9 PCT PASSIVE STAKE IN TRACON PHARMACEUTICALS INC AS OF MARCH 27, 2018 - SEC FILING Source text: [https://bit.ly/2pZqDIp] Further company coverage:

02 Apr 2018

BRIEF-TRACON Pharmaceuticals Announces $38.7 Million Private Placement

* TRACON PHARMACEUTICALS ANNOUNCES $38.7 MILLION PRIVATE PLACEMENT

23 Mar 2018

BRIEF-TRACON Pharma Qtrly Loss Per Share $0.37

* TRACON PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

01 Mar 2018

BRIEF-Ambrx And Tracon Pharma Announce Commercialization Agreement For TRC105 In China

* AMBRX AND TRACON PHARMACEUTICALS ANNOUNCE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR TRC105 IN CHINA

21 Dec 2017

BRIEF-Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara

* Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget

14 Nov 2017

BRIEF-Tracon Pharma reports third quarter financial results

* Tracon Pharmaceuticals reports third quarter financial results and provides corporate update

08 Nov 2017

Earnings vs. Estimates